Reply to: ‘Letter to the Editor on “Copathology Progressive Supranuclear Palsy: Does It Matter?”’
暂无分享,去创建一个
[1] R. Taipa,et al. Letter to the Editor on “Copathology in Progressive Supranuclear Palsy: Does It Matter?” , 2020, Movement disorders : official journal of the Movement Disorder Society.
[2] F. Jessen,et al. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy , 2020, JAMA neurology.
[3] John L. Robinson,et al. Distribution patterns of tau pathology in progressive supranuclear palsy , 2020, Acta Neuropathologica.
[4] C. Troakes,et al. Copathology in Progressive Supranuclear Palsy: Does It Matter? , 2020, Movement disorders : official journal of the Movement Disorder Society.
[5] John L. Robinson,et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated , 2018, Brain : a journal of neurology.
[6] J. Trojanowski,et al. Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.
[7] Andrew King,et al. Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium , 2008, Brain pathology.
[8] L. Thal,et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? , 2006, Brain : a journal of neurology.
[9] Istvan Bodi,et al. Staging/typing of Lewy body related alpha-synuclein pathology , 2016 .